SBIR/STTR Research Award

NONINVASIVE DEVICE FOR SEALING VASCULAR ACCESS PUNCTURES

Award identifier ef130536877f125a134b5c9312a48c1d562c6ac16b27dd53cc3d318af5e02955Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$130,965

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
THERUS CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Verbatim from Applicant's Abstract): In the United States alone, over 2.5 million diagnostic catheterization procedures are performed annually. These procedures are not performed without risk, and a number of complications such as hematoma, pseudoaneurysm, and arteriovenous fistula occur that are responsible for considerable morbidity and some mortality. In addition, many of these complications result in considerable increases in hospital stays and their associated costs. A number of commercial devices to seal catheter wounds have been developed and are being marketed; however, these devices have drawbacks-they lack effectiveness, are too expensive, or are diffcult to use. In our preliminary studies, we demonstrated that High Intensity Focused Ultrasound (HITU) can be successfully used to induce hemostasis of catheter wounds in large laboratory animals. Because ultrasound can be applied transcutaneously, the use of HITU for catheter wound closing has considerable promise. In this Phase I application, we propose to (1) develop a device that would use ultrasound imaging and HITU to produce noninvasive catheter wound sealing, (2) test this device on laboratory animals, and (3) investigate any collateral bioeffects of this procedure. The Phase II study would utilize these results to build a model for human use. In Phase III, human clinical trals would be performed. PROPOSED COMMERCIAL APPLICATION: More than 7,000,000 percutaneous catheterization procedures are performed each year, each leaving behind an arterial puncture that must be sealed. The envisioned product would facilitate a rapid, noninvasive means for accomplishing this task. If successful, the product would become a standard of practice because it speeds sealing, increases catheterization laboratory throughput, reduces overnight hospitalizations, and does not require interruption of the patients anticoagulation therapy.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.